Omeros Co. (OMER) Given “Buy” Rating at Maxim Group

Maxim Group reissued their buy rating on shares of Omeros Co. (NASDAQ:OMER) in a research report released on Friday morning. The firm currently has a $22.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $19.00.

OMER has been the topic of a number of other research reports. Wedbush restated an outperform rating and issued a $47.00 target price on shares of Omeros in a research note on Thursday, January 5th. WBB Securities restated a buy rating and issued a $75.00 target price on shares of Omeros in a research note on Thursday, November 17th. Zacks Investment Research upgraded Omeros from a sell rating to a hold rating in a research note on Thursday, March 9th. FBR & Co restated a buy rating on shares of Omeros in a research note on Thursday, March 2nd. Finally, Needham & Company LLC restated a buy rating and issued a $22.00 target price (down previously from $24.00) on shares of Omeros in a research note on Friday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Omeros presently has a consensus rating of Buy and an average target price of $33.38.

Shares of Omeros (NASDAQ:OMER) traded up 12.90% during trading on Friday, hitting $11.90. 950,358 shares of the stock traded hands. The company has a 50 day moving average price of $11.05 and a 200 day moving average price of $10.51. The firm’s market cap is $510.69 million. Omeros has a 12 month low of $7.20 and a 12 month high of $16.38.

var userip;Your IP Address: document.write(userip);

Hedge funds have recently made changes to their positions in the company. First Allied Advisory Services Inc. bought a new stake in shares of Omeros during the fourth quarter worth $108,000. Nwam LLC boosted its stake in shares of Omeros by 12.5% in the third quarter. Nwam LLC now owns 23,393 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 2,600 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Omeros during the fourth quarter worth $263,000. Gradient Investments LLC boosted its stake in shares of Omeros by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 814 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in shares of Omeros by 52.1% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 34,258 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 11,734 shares in the last quarter. 47.94% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Ratings for Omeros Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition


© 2006-2017 Ticker Report. Google+.